A meta-analysis of 18FDG-PET–CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer

Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 Brown, 2005, Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors, J Natl Cancer Inst, 97, 59, 10.1093/jnci/dji002 Schirrmeister, 2004, Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer, Eur J Nucl Med Mol Imaging, 31, 964, 10.1007/s00259-004-1492-2 D’Addario, 2010, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v116, 10.1093/annonc/mdq189 Schmidt, 2009, Whole-body MRIfor the staging and follow-up of patients with metastasis, Eur J Radiol, 70, 393, 10.1016/j.ejrad.2009.03.045 Fischer, 2009, Preoperative staging of lung cancer with combined PET–CT, N Engl J Med, 361, 32, 10.1056/NEJMoa0900043 van Tinteren, 2002, Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial, Lancet, 359, 1388, 10.1016/S0140-6736(02)08352-6 Berlin, 1997, Does blinding of readers affect the results of meta-analyses? university of Pennsylvania meta-analysis blinding study group, Lancet, 350, 185, 10.1016/S0140-6736(05)62352-5 Whiting, 2003, The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews, BMC Med Res Methodol, 3, 25, 10.1186/1471-2288-3-25 Huedo-Medina, 2006, Assessing heterogeneity in meta-analysis: Q statistic or I2 index?, Psychol Methods, 11, 193, 10.1037/1082-989X.11.2.193 Moses, 1993, Combining independent studies of a diagnostic test into a summary ROC curve: dataanalytic approaches and some additional considerations, Stat Med, 12, 1293, 10.1002/sim.4780121403 Deeks, 2005, The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed, J Clin Epidemiol, 58, 882, 10.1016/j.jclinepi.2005.01.016 Bury, 1998, Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer, Eur J Nucl Med, 25, 1244, 10.1007/s002590050291 Earnest, 1999, Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study, Radiology, 211, 137, 10.1148/radiology.211.1.r99ap34137 Hsia, 2002, Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium −99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer, Neoplasma, 49, 267 Gayed, 2003, Comparison of bone and 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in the evaluation of bony metastases in lung cancer, Mol Imaging Biol, 5, 26, 10.1016/S1536-1632(03)00036-2 Cheran, 2004, Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer, Lung Cancer, 44, 317, 10.1016/j.lungcan.2003.11.008 Ebert, 2004, Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients, Anticancer Res, 24, 3193 Erturan, 2005, The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer, Chest, 127, 449, 10.1378/chest.127.2.449 Fischer, 2007, A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis, Ann Oncol, 18, 338, 10.1093/annonc/mdl374 Ohno, 2007, Whole-body MR imaging vs FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients, J Magn Reson Imaging, 26, 498, 10.1002/jmri.21031 Ursavas, 2007, Can clinical factors be determinants of bone metastases in nonsmall cell lung cancer?, Ann Thorac Med, 2, 9, 10.4103/1817-1737.30355 Heusner, 2009, “One-stop-shop” staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases?, Eur J Radiol Krüger, 2009, Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT, Eur J Nucl Med Mol Imaging, 36, 1807, 10.1007/s00259-009-1181-2 Min, 2009, The role of whole-body FDG PET/CT Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer, J Korean Med Sci, 24, 275, 10.3346/jkms.2009.24.2.275 Song, 2009, Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer, Lung Cancer, 65, 333, 10.1016/j.lungcan.2008.12.004 Takenaka, 2009, Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy, J Magn Reson Imaging, 30, 298, 10.1002/jmri.21858 Liu, 2010, Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT, Eur J Radiol, 74, 231, 10.1016/j.ejrad.2009.01.036 Fogelman, 2005, Positron emission tomography and bone metastases, Semin Nucl Med, 35, 135, 10.1053/j.semnuclmed.2004.11.005 Lardinois, 2003, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N Engl J Med, 348, 2500, 10.1056/NEJMoa022136 Pieterman, 2000, Preoperative staging of non-small-cell lung cancer with positron-emission tomography, N Engl J Med, 343, 254, 10.1056/NEJM200007273430404 van Westreenen, 2004, Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer, J Clin Oncol, 22, 3805, 10.1200/JCO.2004.01.083 Bossuyt, 2003, The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration, Clin Chem, 49, 7, 10.1373/49.1.7